WO2007054600A3 - Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación - Google Patents

Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación Download PDF

Info

Publication number
WO2007054600A3
WO2007054600A3 PCT/ES2006/070171 ES2006070171W WO2007054600A3 WO 2007054600 A3 WO2007054600 A3 WO 2007054600A3 ES 2006070171 W ES2006070171 W ES 2006070171W WO 2007054600 A3 WO2007054600 A3 WO 2007054600A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
glycoisoforms
septicemia
prevention
treatment
Prior art date
Application number
PCT/ES2006/070171
Other languages
English (en)
French (fr)
Other versions
WO2007054600B1 (es
WO2007054600A2 (es
Inventor
Ricardo Agustin Lopez
Marcelo Gustavo Daelli
Bacci Dardo Alexis Pereira
Gabriel Ignacio Amadeo
Miriam Patricia Pereiro
Cristina Noemi Artana
Nestor Maskin
Bernardo Cesar Pistillo
Original Assignee
Protech Pharma S A
Ricardo Agustin Lopez
Marcelo Gustavo Daelli
Bacci Dardo Alexis Pereira
Gabriel Ignacio Amadeo
Miriam Patricia Pereiro
Cristina Noemi Artana
Nestor Maskin
Bernardo Cesar Pistillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protech Pharma S A, Ricardo Agustin Lopez, Marcelo Gustavo Daelli, Bacci Dardo Alexis Pereira, Gabriel Ignacio Amadeo, Miriam Patricia Pereiro, Cristina Noemi Artana, Nestor Maskin, Bernardo Cesar Pistillo filed Critical Protech Pharma S A
Priority to AU2006313672A priority Critical patent/AU2006313672B2/en
Priority to ES06820043T priority patent/ES2396439T3/es
Priority to MX2008006159A priority patent/MX2008006159A/es
Priority to CA2629304A priority patent/CA2629304C/en
Priority to US12/093,365 priority patent/US8343917B2/en
Priority to EP06820043A priority patent/EP1947115B1/en
Priority to BRPI0618498-7A priority patent/BRPI0618498A2/pt
Publication of WO2007054600A2 publication Critical patent/WO2007054600A2/es
Publication of WO2007054600A3 publication Critical patent/WO2007054600A3/es
Publication of WO2007054600B1 publication Critical patent/WO2007054600B1/es
Priority to IL191279A priority patent/IL191279A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Combinación de glicoisoformas de eritropoyetina, en donde dichas glicoisoformas pueden comprender una cantidad de ácido siálico de entre 4 a 10 moléculas de ácido siálico por molécula de eritropoyetinala, la combinación de glicoisoformas se puede usar para el tratamiento o prevención de la septicemia/sepsis, una composición farmacéutica que comprende a dicha combinación, una línea celular productora de una combinación de glicoisoformas de eritropoyetina, procedimientos para obtener la línea celular, procedimiento para producir dicha combinación de glicoisoformas y métodos de tratamiento y prevención de la septicemia/sepsis.
PCT/ES2006/070171 2005-11-10 2006-11-07 Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación WO2007054600A2 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2006313672A AU2006313672B2 (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical composition comprising such combination, procedures to obtain the cell line, procedures to produce such combination of glycoisoforms, and sepsis treatment and prevention methods
ES06820043T ES2396439T3 (es) 2005-11-10 2006-11-07 Combinación de glicoisoformas para el tratamiento o la prevención de la septicemia, línea celular transgénica que produce glicoisoformas de eritropoyetina, composición farmacéutica que comprende dicha combinación, procedimiento para obtener la línea celular, procedimiento para producir la combinación de glicoisoformas y procedimientos para el tratamiento y la prevención de la septicemia
MX2008006159A MX2008006159A (es) 2005-11-10 2006-11-07 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composiciones farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea
CA2629304A CA2629304C (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination
US12/093,365 US8343917B2 (en) 2005-11-10 2006-11-07 Combination of erythropoietin glycoisoforms
EP06820043A EP1947115B1 (en) 2005-11-10 2006-11-07 Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination, method of obtaining the cell line, method of producing the combination of glycoisoforms and methods for the treatment and prevention of septicaemia
BRPI0618498-7A BRPI0618498A2 (pt) 2005-11-10 2006-11-07 combinação de glicoisoformas para o tratamento ou a prevenção da septicemia, linha celular transgênica produtora de glicoformas de eritropoietina, composição farmacêutica incluindo tal combinação, procedimentos para obtenção da linha celular, procedimentos para produção de tal combinação de glicoisoformas e métodos para tratamento e prevenção da septicemia
IL191279A IL191279A (en) 2005-11-10 2008-05-06 Combination of glycoisoforms for the treatment or prevention of sepsis, transgenic cell line producing erythropoietin glycoisoforms, pharmaceutical compositions comprising such combination, procedures to obtain the cell line and procedures to produce such combination of glycoisoforms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP050104712 2005-11-10
ARP050104712A AR053416A1 (es) 2005-11-10 2005-11-10 Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac

Publications (3)

Publication Number Publication Date
WO2007054600A2 WO2007054600A2 (es) 2007-05-18
WO2007054600A3 true WO2007054600A3 (es) 2007-07-19
WO2007054600B1 WO2007054600B1 (es) 2007-10-18

Family

ID=38023621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2006/070171 WO2007054600A2 (es) 2005-11-10 2006-11-07 Combinación de glicoisoformas para el tratamiento o prevención de la septicemia, línea celular transgénica productora de glicoformas de eritropoyetina, composición farmacéutica que comprende a dicha combinación

Country Status (12)

Country Link
US (1) US8343917B2 (es)
EP (1) EP1947115B1 (es)
AR (1) AR053416A1 (es)
AU (1) AU2006313672B2 (es)
BR (1) BRPI0618498A2 (es)
CA (1) CA2629304C (es)
ES (1) ES2396439T3 (es)
IL (1) IL191279A (es)
MA (1) MA30010B1 (es)
MX (1) MX2008006159A (es)
WO (1) WO2007054600A2 (es)
ZA (1) ZA200805044B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112741895A (zh) * 2021-01-19 2021-05-04 中国人民解放军陆军军医大学 Epo类似物在制备治疗脓毒症药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411678A1 (en) * 1984-12-04 1991-02-06 Genetics Institute, Inc. Method for the production of erythropoietin
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
WO2003046162A2 (en) * 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
WO2003046187A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Method for producing a recombinant polypeptide
US20050181359A1 (en) * 1999-04-15 2005-08-18 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
WO1999028455A1 (de) 1997-12-03 1999-06-10 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US20020169129A1 (en) 1998-02-04 2002-11-14 Zaharia Veronica C. Method for improving the quality of life of patients by administration of erythropoietin (RhuEPO)
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
BR9917606A (pt) * 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
CA2437272A1 (en) 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified erythropoietin (epo) with reduced immunogenicity
BR0213402A (pt) * 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
CN1612747A (zh) 2002-01-09 2005-05-04 克鲁塞尔荷兰公司 促红细胞生成素在预防或治疗心力衰竭中的用途
ATE363541T1 (de) 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US20040198663A1 (en) 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
CA2527665A1 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411678A1 (en) * 1984-12-04 1991-02-06 Genetics Institute, Inc. Method for the production of erythropoietin
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
WO2000063403A2 (en) * 1999-04-15 2000-10-26 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US20050181359A1 (en) * 1999-04-15 2005-08-18 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003046162A2 (en) * 2001-11-28 2003-06-05 Polymun Scientific Immunbiologische Forschung Gmbh Process for the production of polypeptides in mammalian cell cultures
WO2003046187A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Method for producing a recombinant polypeptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALAM J. ET AL.: "Apoptosis: target for nov the drugs", TRENDS IN BIOTECHNOLOGY, vol. 21, no. 11, November 2003 (2003-11-01), pages 479 - 483, XP004467494 *
CLAESSENS Y.E. ET AL.: "Sepsis et inflammation", ANNALES FRANCAISES D'ANESTHESIE ET DE REANIMATION, vol. 24, no. 9, 10 July 2005 (2005-07-10), pages 1012 - 1015, XP005066042 *
KOROGLU T.F. ET AL.: "Erythropoietin attenuates lipopolysaccharide-induced splenic and thymic apoptosis in rats", PHYSIOL. RES., vol. 55, no. 3, 2006, pages 309 - 316, XP008083500 *
See also references of EP1947115A4 *

Also Published As

Publication number Publication date
MX2008006159A (es) 2008-10-09
AU2006313672B2 (en) 2011-12-08
IL191279A (en) 2012-05-31
AU2006313672A1 (en) 2007-05-18
EP1947115B1 (en) 2012-10-17
AR053416A1 (es) 2007-05-09
WO2007054600B1 (es) 2007-10-18
WO2007054600A2 (es) 2007-05-18
EP1947115A2 (en) 2008-07-23
ES2396439T3 (es) 2013-02-21
EP1947115A4 (en) 2010-03-03
MA30010B1 (fr) 2008-12-01
CA2629304C (en) 2012-12-04
ZA200805044B (en) 2009-08-26
BRPI0618498A2 (pt) 2011-09-06
US8343917B2 (en) 2013-01-01
US20090220595A1 (en) 2009-09-03
CA2629304A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2009149171A3 (en) Fgf21 mutants and uses thereof
WO2010042747A3 (en) Fgf21 mutants and uses thereof
PL1960600T3 (pl) Produkt bibułkowy traktowany kompozycją substancji dodatkowych i sposób jego wytwarzania
WO2007133183A3 (en) Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
IL230052A0 (en) A method for vaccination against 4 serotypes of dengue
WO2007106469A3 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
IL197768A0 (en) Immunisation method against the 4 dengue serotypes
WO2006099258A8 (en) Tigecycline compositions and methods of preparation
FR2983199B1 (fr) Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2009088572A3 (en) Method of treating erythropoietin hyporesponsive anemias
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2009036067A3 (en) Molecule production by photosynthetic organisms
WO2007106738A3 (en) Acrylated hyaluronic acid
WO2007038571A3 (en) Prolyl hydroxylase antagonists
WO2007133184A3 (en) Polypeptides and biosynthetic pathways for the production of stereoisomers of monatin and their precursors
EP1876228A4 (en) PROCESS FOR MANUFACTURING ALCOHOLIC SOFT DRINK AND ALCOHOLIC BEVERAGE PRODUCED BY THIS PROCESS
WO2007103105A3 (en) Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ATE478742T1 (de) Befestigungselement für bauelemente des trockenbaus und verfahren zur herstellung eines solchen befestigungselements
WO2007067433A3 (en) Poly(trimethylene terephthalate)/poly(alpha-hydroxy acid) films
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2006116703A3 (en) Methods and models for stress-induced analgesia
ZA200804660B (en) Method for the production of y-linolenic acid and/or stearidonic acid in transgenic brassicaceae and linaceae
DE112006000984A5 (de) Verfahren zur Herstellung von 2,5-substituierten Tetrahydropyran-Derivaten durch reduktive Eliminierung des entsprechenden 4-Halogen-Derivats
WO2008049920A3 (en) Il-21 variants

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 191279

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/006159

Country of ref document: MX

Ref document number: 2629304

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006820043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006313672

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06820043

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2006313672

Country of ref document: AU

Date of ref document: 20061107

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006313672

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006820043

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12093365

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0618498

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080509